Latest news with #SobhagyaCapitalOptions
Time of India
11-07-2025
- Business
- Time of India
Asston Pharma SME IPO booked over 32 times on Day 3. Check GMP and other details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, has garnered strong investor interest across all categories, with the issue subscribed a massive 32.13 times ahead of its closing on July 11, 2025. Retail investors led the surge, subscribing 37.58 times their allotted quota, followed by high-net-worth individuals (HNIs) at 51.40 times. Qualified institutional buyers (QIBs) also showed strong interest, subscribing 7.98 times — underscoring broad-based confidence in the company's growth trajectory and global expansion plans. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO aims to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. The IPO has generated moderate interest in the grey market, where it is commanding a premium of Rs 30 over the upper issue price of Rs 123 — implying a 24% grey market premium (GMP). The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. Sobhagya Capital Options is the lead manager to the issue, Maashitla Securities is acting as the registrar, and JSK Securities and Services will serve as the market maker. Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a wide range of pharmaceutical products, including tablets, capsules, syrups, and sachets. The company operates across multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and adhere to stringent quality management protocols. The IPO proceeds will be used to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital requirements (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses. Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% surge in profit after tax compared to the previous fiscal. The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore.
Economic Times
09-07-2025
- Business
- Economic Times
Asston Pharmaceuticals IPO opens for subscription with decent GMP. Check details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, opened for public subscription today. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO seeks to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. ADVERTISEMENT The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols. ADVERTISEMENT The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal. ADVERTISEMENT The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
09-07-2025
- Business
- Time of India
Asston Pharmaceuticals IPO opens for subscription with decent GMP. Check details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products , opened for public subscription today. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO seeks to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market maker. Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and sachets. The company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols. The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses. Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal. The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ETMarkets WhatsApp channel )
